Pharma Mar, S.A.

MCE PHM.MC

Pharma Mar, S.A. Dividend Yield on January 14, 2025: 0.95%

Pharma Mar, S.A. Dividend Yield is 0.95% on January 14, 2025, a -44.41% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Pharma Mar, S.A. 52-week high Dividend Yield is 2.68% on April 19, 2024, which is 180.61% above the current Dividend Yield.
Pharma Mar, S.A. 52-week low Dividend Yield is 0.86% on November 11, 2024, which is -9.43% below the current Dividend Yield.
Pharma Mar, S.A. average Dividend Yield for the last 52 weeks is 1.69%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	509
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Key trends

Past 5 years